<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN"
                      "http://www.w3.org/TR/html4/strict.dtd">
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=us-ascii">
<meta name="generator" content="hypermail 2.1.5, see http://www.hypermail.org/">
<title>Extropians: RE: Performance enhancement with selegiline</title>
<meta name="Author" content="gts (gts_2000@yahoo.com)">
<meta name="Subject" content="RE: Performance enhancement with selegiline">
<meta name="Date" content="2003-02-17">
<style type="text/css">
body {color: black; background: #ffffff}
h1.center {text-align: center}
div.center {text-align: center}
</style>
</head>
<body>
<h1>RE: Performance enhancement with selegiline</h1>
<!-- received="Mon Feb 17 02:14:47 2003" -->
<!-- isoreceived="20030217091447" -->
<!-- sent="Mon, 17 Feb 2003 04:16:24 -0500" -->
<!-- isosent="20030217091624" -->
<!-- name="gts" -->
<!-- email="gts_2000@yahoo.com" -->
<!-- subject="RE: Performance enhancement with selegiline" -->
<!-- id="000001c2d665$408341a0$604a87d8@MyPC" -->
<!-- charset="us-ascii" -->
<!-- inreplyto="000f01c2d576$0f545f00$6401a8c0@dimension" -->
<!-- expires="-1" -->
<p>
<strong>From:</strong> gts (<a href="mailto:gts_2000@yahoo.com?Subject=RE:%20Performance%20enhancement%20with%20selegiline"><em>gts_2000@yahoo.com</em></a>)<br>
<strong>Date:</strong> Mon Feb 17 2003 - 02:16:24 MST
</p>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2846.html">avatar: "Robo Sapiens"</a>
<ul>
<li><strong>Previous message:</strong> <a href="2844.html">Ramez Naam: "Bush budget has 0 dollars for Afghanistan"</a>
<li><strong>In reply to:</strong> <a href="2779.html">Rafal Smigrodzki: "Re: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="2848.html">gts: "RE: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="2848.html">gts: "RE: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="2863.html">Rafal Smigrodzki: "RE: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2845">[ date ]</a>
<a href="index.html#2845">[ thread ]</a>
<a href="subject.html#2845">[ subject ]</a>
<a href="author.html#2845">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<hr>
<!-- body="start" -->
<p>
Rafal wrote:
<br>
<p>[gts wrote]
<br>
<em>&gt;&gt; Rafal hangs his hat on a single study in which selegiline (deprenyl)
</em><br>
<em>&gt;&gt; slowed the progression of Parkinson's disease symptoms (a remarkable
</em><br>
<em>&gt;&gt; result!) but in which the drug was not found to actually extend the
</em><br>
<em>&gt;&gt; life of those same Parkinson's patients.
</em><br>
<em>&gt; 
</em><br>
<em>&gt; ### I explained before but can do it again: selegiline did not slow
</em><br>
<em>&gt; the progression of symptoms, merely symptomatically delayed the time
</em><br>
<em>&gt; to levodopa, as shown by the loss of efficacy during washout.
</em><br>
<p>I stand by my words. Selegiline delayed the time to which symptoms
<br>
become severe enough to require treatment with levodopa. That is
<br>
&quot;slowing the progression of Parkinson's disease symptoms&quot; by anyone's
<br>
definition, Rafal. 
<br>
<p>The only disappointing thing about that particular study is that these
<br>
patients did not also live longer than those who were treated with
<br>
levodopa alone. A plethora of research outside of that study supports a
<br>
neuroprotective role for selegiline, and in fact that study did not
<br>
actually disprove such a role. We can try to infer from the mortality
<br>
rates that there was no significant difference in neuroprotection vs
<br>
controls, but that inference may be incorrect. As far as I know the
<br>
number of existing dopamine neurons were not actually assayed at death,
<br>
leaving open the possibility that PD killed the selegiline+levodopa
<br>
treated patients at about the same rate as the levodopa patients for
<br>
reasons unrelated to the number of functional dopaminergic neurons.
<br>
<p><p>-gts
<br>
<!-- body="end" -->
<hr>
<ul>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2846.html">avatar: "Robo Sapiens"</a>
<li><strong>Previous message:</strong> <a href="2844.html">Ramez Naam: "Bush budget has 0 dollars for Afghanistan"</a>
<li><strong>In reply to:</strong> <a href="2779.html">Rafal Smigrodzki: "Re: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="2848.html">gts: "RE: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="2848.html">gts: "RE: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="2863.html">Rafal Smigrodzki: "RE: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2845">[ date ]</a>
<a href="index.html#2845">[ thread ]</a>
<a href="subject.html#2845">[ subject ]</a>
<a href="author.html#2845">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<!-- trailer="footer" -->
<hr>
<p><small><em>
This archive was generated by <a href="http://www.hypermail.org/">hypermail 2.1.5</a> 
: Mon Feb 17 2003 - 02:17:25 MST
</em></small></p>
</body>
</html>
